NASDAQ:PSTX

Poseida Therapeutics (PSTX) Stock Forecast, Price & News

$2.34

-0.11 (-4.49%)

(As of 03:10 PM ET)

Compare

Today's Range: $2.28
▼
$2.52
50-Day Range: $1.62
▼
$2.79
52-Week Range: $1.54
▼
$8.82

Volume: 307,183 shs
Average Volume: 814,292 shs
Market Capitalization: $203.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.33

Poseida Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 499.7% Upside
$14.33 Price Target
Short Interest: Healthy
6.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.93
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.46) to ($1.82) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

244th out of 972 stocks

Biological Products, Except Diagnostic Industry

35th out of 158 stocks

3.5

Analyst's Opinion

Consensus Rating
Poseida Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.33, Poseida Therapeutics has a forecasted upside of 499.7% from its current price of $2.39.
Amount of Analyst Coverage
Poseida Therapeutics has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
6.40% of the float of Poseida Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Poseida Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Poseida Therapeutics has recently decreased by 6.08%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Poseida Therapeutics does not currently pay a dividend.
Dividend Growth
Poseida Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Poseida Therapeutics has received a 73.00% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Poseida Therapeutics is -0.93.

3.3

News and Social Media Coverage

News Sentiment
Poseida Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Poseida Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added Poseida Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Poseida Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.10% of the stock of Poseida Therapeutics is held by insiders.
Percentage Held by Institutions
60.83% of the stock of Poseida Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Poseida Therapeutics are expected to decrease in the coming year, from ($1.46) to ($1.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Poseida Therapeutics is -9.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Poseida Therapeutics is -9.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Poseida Therapeutics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Poseida Therapeutics (NASDAQ:PSTX) Stock

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

PSTX Price History

30 days | 90 days | 365 days | Advanced Chart

PSTX Stock News Headlines

September 20, 2023 | finance.yahoo.com

Institutional investors may adopt severe steps after Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) latest 13% drop adds to a year losses

August 10, 2023 | finance.yahoo.com

News Flash: Analysts Just Made An Upgrade To Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Forecasts

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!

August 9, 2023 | finanznachrichten.de

Poseida Therapeutics, Inc.: Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023

August 8, 2023 | finance.yahoo.com

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

August 8, 2023 | finance.yahoo.com

Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023

August 8, 2023 | msn.com

Why Are Poseida Therapeutics Shares Moving Higher Today?

August 7, 2023 | marketwatch.com

Poseida Therapeutics in $50 Million Investment Deal With Astellas >PSTX

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

August 7, 2023 | marketwatch.com

Poseida Therapeutics Shares Leap on Astellas Investments >PSTX

August 7, 2023 | finance.yahoo.com

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

August 7, 2023 | finance.yahoo.com

Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update

July 31, 2023 | finance.yahoo.com

The past three years for Poseida Therapeutics (NASDAQ:PSTX) investors has not been profitable

July 5, 2023 | finance.yahoo.com

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies

June 26, 2023 | finance.yahoo.com

Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes

June 13, 2023 | markets.businessinsider.com

Poseida Therapeutics (PSTX) Gets a Buy from BTIG

June 1, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Poseida Therapeutics (PSTX)

June 1, 2023 | finance.yahoo.com

Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders

May 23, 2023 | msn.com

HC Wainwright & Co. Reiterates Poseida Therapeutics (PSTX) Buy Recommendation

May 23, 2023 | finance.yahoo.com

Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day

May 22, 2023 | finance.yahoo.com

Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis

May 18, 2023 | finance.yahoo.com

Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting

May 11, 2023 | finance.yahoo.com

Poseida Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

May 10, 2023 | finance.yahoo.com

What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock

May 10, 2023 | finanznachrichten.de

Poseida Therapeutics, Inc.: Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023

May 9, 2023 | msn.com

Poseida Therapeutics GAAP EPS of -$0.45 misses by $0.03, revenue of $10.34M

May 9, 2023 | finance.yahoo.com

Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates

See More Headlines

Receive PSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PSTX Company Calendar

Last Earnings: 8/08/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PSTX
CUSIP: N/A
CIK: 1661460
Web: www.poseida.com
Phone: 858-779-3100
Fax: N/A
Employees: 348
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $14.33
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +512.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-64,000,000.00
Net Margins: -18.64%
Pretax Margin: -18.29%
Return on Equity: -16.77%
Return on Assets: -8.80%

Debt

Debt-to-Equity Ratio: 0.43
Current Ratio: 4.61
Quick Ratio: 4.61

Sales & Book Value

Annual Sales: $130.49 million
Price / Sales: 1.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.18 per share
Price / Book: 1.07

Miscellaneous

Outstanding Shares: 86,920,000
Free Float: 85,091,000
Market Cap: $203.39 million
Optionable: Not Optionable
Beta: 0.05

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Mark J. Gergen J.D. (Age 60)
Pres, CEO & Chairman
Comp: $920.74k

Mr. Harry J. Leonhardt Esq. (Age 66)
J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec.
Comp: $630.23k

Mr. Brent Warner (Age 39)
Pres of Gene Therapy
Comp: $835.93k

Ms. Johanna M. Mylet CPA (Age 36)
Chief Financial Officer

Mr. Loren Wagner
Sr. VP of Global Operations

Ms. Kristin Martin
Chief People & Admin. Officer

Sarah Thailing
Sr. Director of Corp. Communications & IR

Dr. Devon J. Shedlock Ph.D.
Chief Scientific Officer of Cell Therapy

Ms. Lisa Portale
Sr. VP of Regulatory Affairs

Dr. Jeffrey W. Winkelman J.D.
Ph.D., Sr. VP & Chief Patent Counsel

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PSTX Stock - Frequently Asked Questions

Should I buy or sell Poseida Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Poseida Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PSTX shares.
View PSTX analyst ratings or view top-rated stocks.
What is Poseida Therapeutics' stock price forecast for 2023?: 3 equities research analysts have issued 12 month price objectives for Poseida Therapeutics' stock. Their PSTX share price forecasts range from $14.00 to $15.00. On average, they expect the company's share price to reach $14.33 in the next twelve months. This suggests a possible upside of 512.5% from the stock's current price.
View analysts price targets for PSTX or view top-rated stocks among Wall Street analysts.
How have PSTX shares performed in 2023?: Poseida Therapeutics' stock was trading at $5.30 on January 1st, 2023. Since then, PSTX stock has decreased by 55.8% and is now trading at $2.34.
View the best growth stocks for 2023 here.
When is Poseida Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our PSTX earnings forecast.
How were Poseida Therapeutics' earnings last quarter?: Poseida Therapeutics, Inc. (NASDAQ:PSTX) announced its earnings results on Tuesday, August, 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.21. The firm had revenue of $20.01 million for the quarter, compared to analyst estimates of $10 million. Poseida Therapeutics had a negative trailing twelve-month return on equity of 16.77% and a negative net margin of 18.64%.
What ETF holds Poseida Therapeutics' stock ?: Kelly CRISPR & Gene Editing Technology ETF holds 49,027 shares of PSTX stock, representing 3.32% of its portfolio.

What other stocks do shareholders of Poseida Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW), OPKO Health (OPK), Overstock.com (OSTK), Sorrento Therapeutics (SRNE) and SSR Mining (SSRM).
When did Poseida Therapeutics IPO?: (PSTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair served as the underwriters for the IPO.
What is Poseida Therapeutics' stock symbol?: Poseida Therapeutics trades on the NASDAQ under the ticker symbol "PSTX."
How do I buy shares of Poseida Therapeutics?: Shares of PSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Poseida Therapeutics' stock price today?: One share of PSTX stock can currently be purchased for approximately $2.34.
How much money does Poseida Therapeutics make?: Poseida Therapeutics (NASDAQ:PSTX) has a market capitalization of $203.39 million and generates $130.49 million in revenue each year. The company earns $-64,000,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.
How many employees does Poseida Therapeutics have?: The company employs 348 workers across the globe.
How can I contact Poseida Therapeutics?: Poseida Therapeutics' mailing address is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.poseida.com. The company can be reached via phone at 858-779-3100 or via email at ir@poseida.com.

This page (NASDAQ:PSTX) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial